AbbVie Bid for Biotech Could Expand with Experimental Drug
AbbVie is exploring a cash purchase of about $10.9 billion for a biotech developing an experimental eczema drug, a mo...
Explore the primary drivers of risk in Dividend Aristocrats ETF, including sector shifts and interest-rate impacts, with practical mitigation tips.
26,217 articlesAbbVie is exploring a cash purchase of about $10.9 billion for a biotech developing an experimental eczema drug, a mo...
A WSJ investigation claims polymarket paid creators to stage fake winning bets on dummy sites, highlighting risks aro...
Across Europe’s boardrooms, English has emerged as the default language, pushing non-native speakers to the margins i...
Ripple earns a preliminary CASP nod in Luxembourg, signaling EU-wide expansion under MiCA. XRP trades around $1.10 as...
The White House signed two executive orders Friday to accelerate quantum research and shield federal data from future...
Binance withdraws its Greece bid and says it has one week to secure an EU license. The company reiterates that binanc...
JPMORGAN Global Research says the AI-related capital spend is not a fleeting hype cycle but a profitable buildout. Th...
More than half of U.S. adults lack essential estate planning documents, a trend that persists despite rising financia...
A fresh email alleging a secret phone may hold evidence in a missing-person case has sparked online chatter. This gui...
A $1,100 facebook rental looked like a dream in a walkable neighborhood. This guide explains how these scams work, re...
With Kevin Warsh at the helm, the Fed signals a cautious but hawkish tilt. Borrowers should prepare for higher rates ...
A simple on-screen warning can open a doorway to financial ruin. This article unpacks a real-world fake Microsoft ale...